Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Psoriderm is a range of topical coal tar-based formulations developed and marketed by Dermal Laboratories for the treatment of psoriasis. The active ingredient, distilled coal tar, is a complex mixture that exerts anti-proliferative and anti-pruritic effects. It is specifically indicated for sub-acute and chronic plaque psoriasis of the skin and scalp. The mechanism of action involves reducing the excessive rate of mitotic epidermal cell division, thereby restoring normal skin development. The product line includes Psoriderm Cream and Psoriderm Scalp Lotion Shampoo, both of which are approved for use in adults, the elderly, and children. A third formulation, Psoriderm Bath Additive, was discontinued in June 2021.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Psoriderm.